Older drugs' photoreactivity cataloged

Chicago - Tracking the photoreactivity of many medicines that predate U.S. Food and Drug Administration requirements in this area has been an inexact science, but it's becoming less so. That's because an extensive review released in a presentation at "Important Advances in Allergy-Immunology and Dermatology - From the Bench to the Bedside," a recent gathering of allergists, immunologists and dermatologists in Chicago hosted by Northwestern University, outlines photoreactivity data for more than 100 widely used drugs gleaned from more than 150 research articles

Related Videos

Related Content

Advertisement

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Article

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast

Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Article

ReV Up Your Vitiligo Treatment Strategies

Podcast

Ruxolitinib, Educational Initiatives for Managed Care Professionals Play Crucial Role in Optimizing Care in Atopic Dermatitis

Article

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article

Related Content

Advertisement

Seemal Desai, MD, Responds to Study Suggesting Melanoma is Overdiagnosed in White Patients

Article

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast

Facial Skin Cancer Surgery Yields Low and Improved Scores For Perceived Stigmatization, Body Image Concerns, and Psychosocial Distress

Article

ReV Up Your Vitiligo Treatment Strategies

Podcast

Ruxolitinib, Educational Initiatives for Managed Care Professionals Play Crucial Role in Optimizing Care in Atopic Dermatitis

Article

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Article